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Abstract
Despite the individually different molecular alterations in tumors, the malignancy associated
biological traits are strikingly similar. Results of a previous study using renal cell carcinoma
(RCC) as a model pointed towards cancer-related features, which could be visualized as
three groups by microarray based gene expression analysis. In this study, we used a math-
ematic model to verify the presence of these groups in RCC as well as in other cancer
types. We developed an algorithm for gene-expression deviation profiling for analyzing
gene expression data of a total of 8397 patients with 13 different cancer types and normal
tissues. We revealed three common Cancer Transcriptomic Profiles (CTPs) which recurred
in all investigated tumors. Additionally, CTPs remained robust regardless of the functions or
numbers of genes analyzed. CTPs may represent common genetic fingerprints, which
potentially reflect the closely related biological traits of human cancers.
Introduction
The use of DNAmicroarray technologies enabled the generation of myriads of data, sustaining
further molecular sub-classification of many previously described pathologic phenotypes with
significant effects on clinical decision making and prognosis [1–6]. In particular, gene expres-
sion analysis served as an efficient cancer sub-classification tool [7], and is regarded as the
most downstream signal onto which accumulated effects from different molecular layers such
as genomics, proteomics or methylomics may imprint [8]. Depictions of distinct driver muta-
tions in genes such as BRAF, EGFR, PAK5,HER2, ALK or hormone receptors [9, 10], all of
which are embedded in individual tumor specific mutational landscapes [11–13], have also
been used as prognostic or therapeutic biomarkers for further patient stratification of different
cancer subtypes [14–17].
The fact that close to 75% of all genes have already been identified as being potentially can-
cer relevant [18], and the unique molecular make-up of each tumor [19] suggest that cancer
evolution and progression are complex processes. In order to better understand the biology of
tumors, functionally classifying deregulated gene candidates according to specific biologic
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processes is often the practice of choice [20]. Despite the unique molecular background of each
malignant tumor, the “Hallmarks of Cancer” [21] claim that all malignant neoplasms acquire
similar characteristics, enabling the transformation from a normal to a cancer cell.
In line with the proposed concept of cancer hallmarks, we assumed that regardless of their
highly diverse phenotypic and genotypic appearance, all tumors share common cancer traits,
which may potentially be detected via gene expression analysis. This hypothesis is backed by
our recent identification of global gene expression outputs of prognostic relevance in renal cell
carcinoma (RCC) [22]. Based on this finding we evaluated whether similar gene expression
patterns may exist also in other cancer types.
Unbiased by any cancer-specific marker or classification schemes currently used, we ana-
lyzed 55 published studies of gene expression data encompassing a total of 8397 patients with
13 different cancer types by means of gene-expression deviation profiling.
Materials and Methods
RCC patient data
Survival data linked to the published dataset GSE19949 was provided by the Cancer Registry
Zurich and Zug and approved by the ethics committee of the Canton Zurich (KEK-ZH-Nr.
2013–0629). This data was used for the verification of the prognostic relevance (Fig 1) as pro-
posed from our previous work using the same patient cohort [22].
Gene expression data and normalization
All data was retrieved from the GEO repository as published by the authors. An overview of all
analyzed datasets is given in S1 Table. Data were pre-processed and normalized as described in
S1 Text. Table A in S1 Text and S2 Table provide a systematic overview of all analyzed datasets
including clinic-pathological data.
Model generation and algorithm development
The method comprised the following steps: For every normalized log2 gene probe set value, the
mean expression value was calculated over all samples of the given data set. This mean value
was then subtracted from the log2 expression values of all samples. The calculated difference
denoted the individual deviance of the sample from the mean expression value for the respec-
tive probe set.
To those expression values which were close to mean the value 0, to those with significantly
higher values than mean the value 1, and to those with significantly lower expression than
mean the value -1 were assigned. The threshold for high and low was set to 43% of the standard
deviation, which means that all three values (-1, 0, 1) occurred at almost the same frequency.
The value 0 was assigned to those deviation values which were located between -0,43 σ and
+0,43 σ. Deviation values lower than -0,43 σ were assigned with -1, those higher than +0,43 σ
with +1. Additional categories were therefore automatically excluded.
The samples were then clustered using well known clustering methods such as k-means or
SOM, so that samples with similar (individual) profiles were assigned to the same group A, B,
or C. In order to generate the respective CTPs the average values for each probe set and group
were calculated.
At the end of this procedure, a whole genome CTP profile existed for every group, repre-
sented by a vector with a length equal to the number of probe sets of the respective microarray
and values ranging between -1 and 1 (Fig 2 and S1 Text).
Common Genomic Fingerprints of Human Cancers
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For the RCC data set GSE19949 the assignments to A, B, or C groups were known a priori
[22]. Detailed methodological descriptions and codes can further be found in S1 Text. For the
interested reader, raw and calculated data is available upon request.
Fig 1. RCC groups A, B, and C and their correlation with patient survival. Kaplan-Meier curves for overall survival in relation to cancer transcriptome
profiles (CTPs) as described for the patient cohort GSE19949 [22]. Survival data were made available by the Cancer Registry Zurich and Zug.
doi:10.1371/journal.pone.0161514.g001
Common Genomic Fingerprints of Human Cancers
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De Finetti-like mappings
As proposed by de Finetti [23] ternary plots or de Finettimappings are efficient means to
depict percentage compositions for 3 parameters in an equilateral triangle [24, 25]. Using this
method, we were able to plot the distances of individual patient samples obtained from the 3
predefined CTP centroids. Additional info to the de Finetti like mappings can be found in
S1 Text.
Fig 2. Workflow for generating RCC-CTPs. A. Determination of the gene expression value (log2) of gene probe set 1 in all RCC samples tested and
generation of the mean value for probe set 1 of the entire RCC tumor cohort (exemplified values are shown).B. Subtraction of the mean value from true
expression value for probe set 1 of each patient.C. Distribution of the remaining deviation values frommean for probe set 1. D. Annotation of remaining
deviation values frommean for probe set 1 as 1, -1 or 0 depending on their localization in the distribution. E. Steps A to D are performed for all probe sets of
the gene expression microarray. F. Individual CTP profile for each patient given by a vector covering all expression values.G.Grouping of RCC patients into
CTP-A, -B or -C according to Beleut et al. 2012; Determination of the CTPmean values of all gene probe sets for patient group A, group B and group C and
generation of the final RCC CTP A, -B and -C target vectors.H.Gene expression data from other cancer types calculated according to steps A to F and
generation of patient-specific CTP-vectors. I. Correlation of RCC CTP-A, -B and -C target vectors from step G with patient-specific CTP of other cancer types
derived from step H. (BC) breast cancer patients; (LC) lung cancer patients, (CC) colon cancer patients. J. Assigning a patient or control to tumor subgroup
according to the CTP with the highest correlation.
doi:10.1371/journal.pone.0161514.g002
Common Genomic Fingerprints of Human Cancers
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CTP assignment
For each sample of a new data set, the expression profile was calculated as mentioned above.
As for individual samples no averaging takes place, the profiles contained only the values -1, 0,
or 1. The correlations between the sample profile and the whole genome A-, B- and C-CTPs
were calculated. The sample was assigned to the CTP with the highest Pearson correlation
(Figs 2 and 3 and S1 Text).
Results
Genome wide expression analysis confirms three subgroups in two
independent RCC patient cohorts
By analyzing gene expression profiles in a RCC patient cohort (GSE19949) we recently identi-
fied three subgroups (termed groups A, B and C), which were not significantly associated with
pathological prognostic parameters such as nuclear differentiation grade and tumor stage
(Beleut et al., see additional file 12, table S8 [22]). As survival data was sparse at that time point
for this patient cohort, we analyzed a second RCC patient cohort using tissue microarrays and
immunohistochemistry. By correlating survival data and expression levels of proteins whose
genes were highly expressed in the three groups, we found an association between identified
subgroups and patient clinical outcome [22].
As survival data were meanwhile also available for 89 patients of the first cohort, we could con-
firm the result obtained from the second tissue microarray patient cohort. As shown in Fig 1 the
Fig 3. Graphical illustration of CTPs and patient classification. Shown is a graphical overview on the nature of generated RCC-CTPs as well as their
comparison with the CTP of one patient with a different cancer type. The deviation from the mean expression for all probe sets and their relative correlation to
each other (continuous curves) define the RCC-CTP target profiles. For CTP assignment, the CTP profile of an individual patient with another cancer type
(dashed curve) is compared to the target RCC-CTPs.
doi:10.1371/journal.pone.0161514.g003
Common Genomic Fingerprints of Human Cancers
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survival rate was highest for patients belonging to group A followed by group B and group C, with
statistically significant differences between group A versus group C (p-value = 0.040).
Algorithmic Cancer Transcriptomic Profile (CTP) model for subgrouping
RCC
To exclude that those RCC gene-expression signatures are biased due to non-cancerous effects,
we first aimed at designing a comprehensive algorithmic Cancer Transcriptomic Profile (CTP)
classification model using the RCC gene expression data. Requirements for the model included
automated reassignment of GSE19949 RCC tumors to the known CTP groups A, B and C.
Additionally, the algorithms should be independent from biases derived from different normal-
ization techniques as well as tissue type artefacts. Finally, the model should consider the entire
gene expression profile resulting from the microarray chip.
In order to further investigate whether RCCs could be sub-classified by our proposed CTP-
model, we utilized the following approach. We classified the GSE19949 tumors into the three
known groups by implementing the algorithmic workflow shown in Fig 2A–2G.
Fig 4. Visualization of CTPs by de Finetti like mapping. A. De Finetti like diagram illustrating RCC classification of GSE19949 into the three CTP groups
as previously defined [22]. Each dot represents one patient, colors code for the distinct groups, as indicated. B. De Finetti like diagram illustrating the sub-
classification of an independent ccRCC dataset (GSE22541) according to the Beleut et al. 2012 rules. The color code per patient defines its CTP assignment
as identified in A.C. Control de Finetti like diagram, in which Self Organizing Maps (SOM) have been applied in classifying GSE22541 ccRCC primary
tumors for comparison. The color code per patient defines the “CTP” to which the respective tumor would belong according to SOM.D. De Finetti like
diagram illustrating the classification of normal renal tissues of GSE53757 according to identified CTPs. Note the weak correlation of individual samples with
profile vectors, leading to mostly a central clustering of analyzed samples. E. De Finetti like mapping of a breast cancer dataset (GSE12093) and F. a
Lymphoma dataset (GSE34771) according to RCC-CTPs. Note the increased scattering of individual patients in E and F when compared to control.
doi:10.1371/journal.pone.0161514.g004
Common Genomic Fingerprints of Human Cancers
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Fig 3 provides a graphical overview on the nature and comparison of CTPs within RCC (Fig
A in S1 Text). Highest Pearson correlation with one of the three RCC-CTPs assigned a patient
either to CTP group A, B or C.
We visualized achieved results by means of a de Finetti like mapping (23, 25) (Fig 4A) to
better highlight the potential distances for each patient from the respective cluster centroids
defined as A, B and C. Next, we classified an independent set of clear cell RCCs (ccRCC)
(GSE22541), resulting in three similar CTP clear cell RCC cohorts as shown in Fig 4B.
To further solve the question whether other clustering technologies could also have been
used as a potential starting point for CTP identification, we utilized Self Organizing Maps
(SOM) [26] for clustering of GSE22541 and compared achieved results with the classification
shown in Fig 4B (Fig 4C). Result overlap of both technologies was 75%, suggesting that CTPs
can be identified independently of the data set GSE19949 which was the starting point of our
observations and calculations. The similar outcome with the two clustering technologies used
suggests the presence of distinct CTPs in different sets of RCC tumors.
As control, we applied this classification rule on a set of normal renal tissues (GSE53757)
but also on other healthy tissues derived from different organs or anatomic body parts as anno-
tated in GSE1133 and GSE2361. In contrast to RCC, healthy controls remained grouped
around the center of the de Finetti like mapping (Fig 4D and Fig B in S1 Text) confirming RCC
specificity of identified CTPs.
To better investigate cancer specificity in general, we also strictly applied identified
RCC-CTPs on one dataset of breast cancer (Fig 4E) and one dataset of lymphoma (Fig 4F),
respectively. Despite potential cancer-specific background, resulting de Finetti like mappings
still illustrate an increased scattering of individual patients as compared to control mappings,
thus strengthening the assumption of general cancer specificity rather than RCC specificity of
proposed CTPs.
Additionally, we investigated the average correlation of all patients assigned for a particu-
lar CTP (S1 Text). For every CTP of a data set we collected all contributing patients and
their correlation values with the respective CTP and calculated the average. The results may
be interpreted as “cluster diameter” estimate. For RCC, the correlation was highest with
0.439; 0.476; 0.413 for CTP-A, CTP-B and CTP-C, respectively. For the other tumor types,
these values ranged between 0.14 and 0.18, whereas for control normal tissues these values
ranged between 0.08 and 0.14, much lower than for tumors. This difference between normal
and tumor tissue was highly significant (p-value = 210−6). The direct comparison of the
normal and tumor tissue samples of the renal data set GSE53757 (0.08 vs. 0.14, respectively)
was also significant (p-value = 510−6). We intentionally omitted the SOM clustered data
from GSE22541 from this averaging since the independent SOM clustering introduced addi-
tional positional scatter. Detailed results for each GSE dataset and corresponding CTPs are
listed (Table E in S1 Text).
Transferring the CTP model established for RCC to other cancer types
By transferring this RCC based model to gene expression data of other cancer types, we
aimed to regroup other cohorts according to conditions homologous to RCC CTP groups A,
B and C. The CTP model and its transfer to other cancer types occurred as illustrated in Fig
2H–2J. Resulting CTP subgroups of different cancer types were also correlated with associ-
ated clinical data where available. We calculated respective CTPs for all cancer types from
published studies as denoted in S1 Table and compared them with reference RCC-CTPs.
Highest Pearson correlation with one of the three RCC-CTPs assigned a patient either to
CTP group A, B or C.
Common Genomic Fingerprints of Human Cancers
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CTPs are not RCC-specific and commonly exist in cancer
transcriptomes
In order to test whether or not CTPs are exclusively related to RCC, we performed a reverse trans-
fer of the CTP concept (S1 Text). Data from the breast cancer study GSE2603 was used to generate
breast cancer-specific CTPs. Samples from this study were clustered with standard unsupervised
clustering methods (k-means, SOM) into three clusters, and the respective Kaplan-Meier curves
were calculated. The resulting groups were used for transfer to the RCC study GSE19949 with the
same procedure utilized for transfer to other cancer types (reverse transfer). The resulting distribu-
tion into three groups was 65% identical with the original RCC grouping [22] suggesting a nonran-
dom finding and a general presence of CTPs detectable in all human cancers.
CTPs seem to be robust irrespective from gene function and number
Our efforts for the identification of our CTP concept in human cancer types always included
complete sets of genes present on microarray chips. In order to investigate whether indeed all
genes or only specific subsets of genes contributed to CTP vector definition, we chose limited
numbers of either randomly or functionally defined gene subsets [27] for the generation of
CTP target vector profiles using RCC as starting point. We then transduced resulting confined
RCC-CTPs to the expression data of the same genes in all other tumor types and compared
achieved CTP affiliation of each tumor. We observed for all tumors and tumor types that 700
randomly chosen genes led to an overall similarity of 86 ± 6.6%. This held also true when 716
tumor suppressor genes and 690 oncogenes were chosen for CTP calculation (80 ± 7.7% and
81 ± 8.1% similarity, respectively). Specific results for the individual studies are depicted in S3
Table. Our overall finding suggests that CTPs are non-random and measurable irrespective of
gene expression deviations relatively to each other, distinct gene types, gene functions or gene
numbers (Fig 5, S4 and S5 Tables). The data shown in S4 and S5 Tables give examples how
gene sets with different functions (tumor suppressor genes and oncogenes) are classified into 3
CTPs. The relationship of the CTP groups among different cancer types can be visualized by
sorting the values (ascending or descending) obtained from one gene set of one CTP group.
As measuring gene expression is always accompanied by noise, we investigated its impact
by performing a simulation. We asked if the separation between CTP-A, -B, and -C as observed
in Fig 1 may be entirely or to large part due to noise. In the simulation, we thus assumed that
for all patients the deviation from the average expression value of each probe set is just the
result of a random fluctuation. The distribution of the deviations is assumed to be normal for
every probe set. The subsequent discretization of the values, calculation of the CTP profiles
and the ensuing assignment of the virtual patients to a particular CTP was performed accord-
ing to the protocol, as well as the calculation of the “virtual cancer” specific profile. A random
subset of 716 genes was finally picked to mimic the effect of specific gene selection as in the
tumor suppressor or oncogene examples.
For the simulation, we generated 14 virtual cancer patient groups with 50 patients each, sim-
ilar to the experimental situation.
Correlating all CTP-A profiles with each other across different virtual cancer types, and
similarly for CTP-B and -C, yielded average correlations of less than 0.02. Calculating
the same average correlations for the experimental tumor suppressor genes or oncogenes
yielded average correlations between 0.7 and 0.76. The probability that these high correlations
between CTPs across different cancer types were generated by random is infinitesimally small
(p-value< 10−100). Between the two experimental sets, however, the p-values were much
higher (0.04–0.98), indicating that the null hypothesis (generated from the same underlying
distribution and not by noise) held as expected.
Common Genomic Fingerprints of Human Cancers
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A similar result was obtained when the different CTPs within a cancer type were compared.
As expected, experimental correlation values between different CTPs showed values different
from 1, i.e. -0.38 (AB), -0.5 –-0.6 (AC), and -0.37 –-0.51 (BC). Again, these correlations were
stable across the tumor suppressor and oncogenes platform (p-values ranging between 0.25
and 0.98), while the simulation yielded average correlations between 0.008 and 0.21. This dif-
fered significantly from the experimental values (p-value< 0.001).
In summary, these simulations demonstrate that random effects like mere fluctuations of
expression values could not explain the high correlations between CTPs across and within dif-
ferent tumor types.
Fig 5. CTP profiles of the different cancer types using randomly picked tumor suppressor or oncogenes. Shown are best descriptors of gene
expression deviations from the mean of randomly selected tumor suppressor genes (A) and oncogenes (B) encompassing different cancer types. For a
detailed overview illustrating all expression deviations including genes showing no deviations from the mean, see S4 and S5 Tables.Red: relative gene
expression deviation is lower than the mean expression,Green: relative gene expression deviation is higher than the mean expression. CTPs differ by the
overall relative gene expression deviations. The entirety of expression deviations from the mean of genes, not that of one single gene is relevant for affiliating
one distinct tumor to CTP-A, -B or -C.
doi:10.1371/journal.pone.0161514.g005
Common Genomic Fingerprints of Human Cancers
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Discussion
The hallmarks of cancer imply that all cancers follow specific biological concepts which form
the basis of malignant behavior. Therefore, we speculated that such biological concepts among
cancers relate closely to each other and may be visualized by gene expression patterns. Our
hypothesis originated from the detection of three gene expression outputs in renal cell carci-
noma (RCC), which appeared to be independent from pathological parameters and correlated
with patient outcome [22]. In an attempt to further support this hypothesis we designed an
algorithmic model, which enabled us to classify Cancer Transcriptomic Profiles (CTP). The
initial experiment on RCC was performed on Affymetrix arrays. In order to transduce the algo-
rithmic rule on other cancer types in the first step, we focused on studies performed using Affy-
metrix microarrays and screened GEO for surgically treated tumor cohorts with associated
progression data and identified 55 studies. Being aware of additional useful meta-analysis on
different platforms, we noticed that all these platforms lack a proper key to translate their
annotations to each other or to Affymetrix or Illumina or even present entirely different tech-
nologies such as RNAseq. By focusing on a single platform, we could exclude all additional fac-
tors and potential artifacts due to the chip related technical differences. In one instance,
however, we compared the Affymetrix outcome with results obtained from Illumina data to
demonstrate that the observed results are independent of the gene expression platform chosen.
We selected Illumina for this comparison as this platform has about 6000 probes in common
with Affymetrix with equal annotations, thus enabling the partial transfer as performed in our
text appendix. The generalizations found across tumor boundaries could thus be safely attrib-
uted to the underlying tumor biology.
In this study, we analyzed gene expression data obtained from 8397 samples. Sixteen of 55
datasets accounting for 4177 out of the 8387 tumors were from breast cancer, which currently
presents the most frequent tumor type in the GEO repository. We detected three different Can-
cer Transcriptomic Profiles (CTPs) that are recurring in 13 different cancer types. These CTPs
suggest molecular relationships among human cancers.
Absolute gene expression values with subsequent associated gene enrichment technologies
have been used in many gene expression studies. In keeping with this, we first used a similar
approach and detected 3 groups in RCC by two-way non-supervised hierarchical clustering
[22]. Our subsequent goal was to find a mathematic approach, an algorithm, for depicting
those 3 groups. According to our opinion, this was best achieved by discretization of gene
expression data we describe here. The method we have chosen is per se not novel, but to our
knowledge, its conceptual application to characterize mathematically the 3 CTPs has not been
used and published so far. A closer look at the expression profiles of all genes (Fig A in S1
Text) clearly shows that the expression levels of the genes in each CTP group are equally dis-
tributed. CTP groups are not characterized by expression patterns of a specific set of genes (e.g.
high versus low) which differ, for example, between two organs, tissue/cell types or healthy/dis-
eased tissue. As illustrated in Fig 3, it is the composition of the “expression profiles” yielded
from the expression deviations from the mean values from all gene probe sets which defines a
specific CTP. According to our opinion one would hardly be able to identify those 3 CTPs by
using absolute gene expression levels or a more sophisticated “barcoding”model in which gene
expression measurements are banalized to 0 (not expressed) vs. 1 (expressed) [28, 29].
Furthermore, a binary approach would only distinguish between expression levels which
are either low or high in two groups. With the binary approach one focuses only on low
(underexpressed) and high (overexpressed) expressed genes but exclude those genes which are
more or less equally expressed. Our model includes also genes with no or small expression level
changes. A closer look on the 3 CTPs clearly demonstrates that these genes provide similar
Common Genomic Fingerprints of Human Cancers
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contributions to the CTP profiles as the high differentially expressed genes. As a result, CTPs
yielded with a 2-bin system would introduce substantial distortions compared to our CTPs.
These three CTP groups first detected in RCC and confirmed by the discretization method,
were transferable to 12 additional cancer types. We developed the algorithm applied to address
various challenges encountered in transcription analysis, so that individual expression fluctua-
tions per gene or probe set were neutralized. Subsequent to the standard GCRMA normaliza-
tion step for Affymetrix gene expression chips (S1 Text), we normalized and scaled the
expression values of the entire patient set gene-wise. Subsequently we discretized the scaled
expression values into 3 levels (S1 Text). By using our -1,0,1 approach of discretization, which
aimed at turning the continuous and multi-parametric data into this finite number of discrete
elements, we were able to not only facilitate ensuing computations, but also reduce data noise.
Clustering the discretized data of the RCC study GSE19949 for 3 Cancer Transcriptome Pro-
files (CTP-A, -B, -C) with different methods (e.g., k-means, SOM) and an independent classifi-
cation based on histological parameters [22], yielded almost identical results. Elements of our
approach relate to methods applied earlier, such as Linear Discriminant Analysis, Significance
Analysis of Microarrays [30] or shrunken centroids [31]. One of the most relevant advantages
is that this method is invariant against differences in expression levels resulting from different
tissues of origin. It thus may present a novel method enabling the detection of pan-cancer
signatures.
According to our mathematical approach, CTPs are a reappearing pattern throughout the
cancer transcriptomes. Notably, different clustering technologies, such as k-means or SOM
[26, 32], applied after discretization generated similar results. The robust nature of a defined
CTP in a tumor was also demonstrated when we investigated the average correlation of all
patients assigned for a particular CTP. Despite potential biases which may be caused when cal-
culating with data sets generated from different patient cohorts in different laboratories, the
difference of the correlation values obtained from normal and tumor tissue was highly signifi-
cant. Even the reverse transfer of breast cancer-specific CTPs to RCC resulted in 3 groups
which were 65% identical with the original RCC subgrouping further supporting the existence
of CTPs in different cancers.
It is of note that due to the very limited availability of samples from normal (control) tissue
published in GEO, it is currently not possible to define the particular threshold between normal
and tumor tissue. We noticed that the studies mostly consist of disease sample collections with
no corresponding healthy counterparts. Therefore, a healthy/disease threshold could not be
yielded, unless by including matched pairs of affected and non-affected tissue samples in a suf-
ficiently large amount. The de Finetti-like visualizations demonstrate, however, that normal
samples located closer to the triangle center than tumor samples. At the center, the correlation
with any of the CTP was lowest, pointing to a lower CTP differentiation in normal tissue sam-
ples. Being limited to the present situation, however, we can only state, as shown in the results
part, that the defined calculated differences are highly significant (p-value = 210−6) and are
not occurring due to randomness.
Finally, CTPs still remained stable with sets of only several hundred genes, whether ran-
domly or non-randomly selected. Therefore, we conclude that i. the expression status of every
single gene is important to contribute to a CTP and ii. the expression profile of a minimum set
of genes is required to yield a CTP.
As the CTPs of our RCC indicated correlation with patient outcome, we calculated Kaplan
Meier survival plots using all survival data sets from different cancer types that were available
in the GEO database. The results were, however, difficult to interpret (data not shown). Some
survival plots for sarcoma, breast and lung cancer were similar to those obtained from RCC.
Other survival plots showed no associations or, as in the case of ovarian cancer, even
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contrasting patterns. This data strongly suggest that the analysis of survival data sets from dif-
ferent patient cohorts (S1 and S2 Tables) generated from different research groups, as well as
the use of different assay and standardization methods may cause dataset bias and inter-dataset
noise. The GEO database presents to our knowledge the major resource for researchers for get-
ting access to clinical survival data. Based on our experience its use for analyzing the prognostic
value of molecular markers in one specific tumor type or in different cancers is rather limited.
However, this tool is ideally suited to perform comprehensive analysis to detect potential asso-
ciations between molecular signatures and cancer.
Conclusions
We present a novel model that can be applied to identify cancer-specific gene expression pro-
files. It has been widely accepted that each tumor has developed its own individual molecular
landscape. The entirety of molecular events leading to a malignant tumor affects always the
same biological concepts described in the hallmarks of cancer. We believe that the CTPs identi-
fied by us represent the molecular outputs which exist in all human cancers. However, more
in-depth investigations with larger and better defined cancer patient cohorts are needed to sup-
port our CTP concept for cancer biology but also as possible additional tool for cancer
prognosis.
Supporting Information
S1 Table. All studies considered for CTP affiliation.
(XLSX)
S2 Table. Clinico-pathological parameters per CTPs.
(XLSX)
S3 Table. CTP affiliation and similarity by considering randomly chosen genes.
(XLSX)
S4 Table. CTPs and Tumor Suppressor Genes in different cancer types.
(XLSX)
S5 Table. CTPs and Oncogenes in different cancer types.
(XLSX)
S1 Text. Additional methods, results and figures.
(DOCX)
Acknowledgments
We thank HS Lifesciences GmbH for supporting this project, Andreas Brede-Buchenau, Mar-
tin Wiesenfeldt and Ruediger Goetz for critical proofreading and valuable comments.
Author Contributions
Conceptualization:MB PS.
Data curation: RS ME RG CM.
Formal analysis: RS ME RG.
Funding acquisition: KH HM.
Methodology:MB RS ME RG.
Common Genomic Fingerprints of Human Cancers
PLOS ONE | DOI:10.1371/journal.pone.0161514 August 18, 2016 12 / 14
Resources: SD KH HM.
Supervision:MB.
Validation:MB RS ME RG CM.
Visualization:MBME RG CM.
Writing - original draft:MB PS.
Writing - review & editing:MBME RG CM PS.
References
1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human
breast tumours. Nature. 2000; 406(6797):747–52. doi: 10.1038/35021093 PMID: 10963602.
2. Burgess DJ. Gene expression: colorectal cancer classifications. Nature reviews Cancer. 2013; 13
(6):380–1. doi: 10.1038/nrc3529 PMID: 23640209.
3. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification
of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999; 286
(5439):531–7. PMID: 10521349.
4. West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, et al. A novel classification of lung
cancer into molecular subtypes. PloS one. 2012; 7(2):e31906. doi: 10.1371/journal.pone.0031906
PMID: 22363766; PubMed Central PMCID: PMC3283716.
5. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature
as a predictor of survival in breast cancer. The New England journal of medicine. 2002; 347(25):1999–
2009. doi: 10.1056/NEJMoa021967 PMID: 12490681.
6. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large
B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503–11. doi: 10.
1038/35000501 PMID: 10676951.
7. Rhodes DR, Chinnaiyan AM. Integrative analysis of the cancer transcriptome. Nature genetics. 2005;
37 Suppl:S31–7. doi: 10.1038/ng1570 PMID: 15920528.
8. Sohn KA, Kim D, Lim J, Kim JH. Relative impact of multi-layered genomic data on gene expression
phenotypes in serous ovarian tumors. BMC systems biology. 2013; 7 Suppl 6:S9. doi: 10.1186/1752-
0509-7-S6-S9 PMID: 24521303; PubMed Central PMCID: PMC3906601.
9. Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA. Molecular
markers for breast cancer: prediction on tumor behavior. Disease markers. 2014; 2014:513158. doi:
10.1155/2014/513158 PMID: 24591761; PubMed Central PMCID: PMC3925609.
10. Zhou JX, Yang H, Deng Q, Gu X, He P, Lin Y, et al. Oncogenic driver mutations in patients with non-
small-cell lung cancer at various clinical stages. Annals of oncology: official journal of the European
Society for Medical Oncology / ESMO. 2013; 24(5):1319–25. doi: 10.1093/annonc/mds626 PMID:
23277484.
11. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic muta-
tion in human cancer genomes. Nature. 2007; 446(7132):153–8. doi: 10.1038/nature05610 PMID:
17344846; PubMed Central PMCID: PMC2712719.
12. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A com-
prehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010; 463
(7278):191–6. doi: 10.1038/nature08658 PMID: 20016485; PubMed Central PMCID: PMC3145108.
13. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009; 458(7239):719–24. doi: 10.
1038/nature07943 PMID: 19360079; PubMed Central PMCID: PMC2821689.
14. Liu YJ, Shen D, Yin X, Gavine P, Zhang T, Su X, et al. HER2, MET and FGFR2 oncogenic driver alter-
ations define distinct molecular segments for targeted therapies in gastric carcinoma. British journal of
cancer. 2014; 110(5):1169–78. doi: 10.1038/bjc.2014.61 PMID: 24518603; PubMed Central PMCID:
PMC3950883.
15. Fawdar S, Edwards ZC, Brognard J. Druggable drivers of lung cancer. Oncotarget. 2013; 4(9):1334–5.
PMID: 23963079; PubMed Central PMCID: PMC3824536.
16. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver
mutations in melanoma. Cell. 2012; 150(2):251–63. doi: 10.1016/j.cell.2012.06.024 PMID: 22817889;
PubMed Central PMCID: PMC3600117.
Common Genomic Fingerprints of Human Cancers
PLOS ONE | DOI:10.1371/journal.pone.0161514 August 18, 2016 13 / 14
17. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. Vemurafenib: the first drug approved for
BRAF-mutant cancer. Nature reviews Drug discovery. 2012; 11(11):873–86. doi: 10.1038/nrd3847
PMID: 23060265.
18. Huret JL, Ahmad M, Arsaban M, Bernheim A, Cigna J, Desangles F, et al. Atlas of genetics and cytoge-
netics in oncology and haematology in 2013. Nucleic acids research. 2013; 41(Database issue):D920–
4. doi: 10.1093/nar/gks1082 PMID: 23161685; PubMed Central PMCID: PMC3531131.
19. Ogino S, Fuchs CS, Giovannucci E. Howmany molecular subtypes? Implications of the unique tumor
principle in personalized medicine. Expert review of molecular diagnostics. 2012; 12(6):621–8. doi: 10.
1586/erm.12.46 PMID: 22845482; PubMed Central PMCID: PMC3492839.
20. Chittenden TW, Howe EA, Culhane AC, Sultana R, Taylor JM, Holmes C, et al. Functional classification
analysis of somatically mutated genes in human breast and colorectal cancers. Genomics. 2008; 91
(6):508–11. doi: 10.1016/j.ygeno.2008.03.002 PMID: 18434084; PubMed Central PMCID:
PMC2492759.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646–74. doi:
10.1016/j.cell.2011.02.013 PMID: 21376230.
22. Beleut M, Zimmermann P, Baudis M, Bruni N, Buhlmann P, Laule O, et al. Integrative genome-wide
expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different
patient outcome. BMC cancer. 2012; 12:310. doi: 10.1186/1471-2407-12-310 PMID: 22824167;
PubMed Central PMCID: PMC3488567.
23. de Finetti. La Prévision: Ses Lois Logi ques, ses Sources Subjectives. Annales de l'Institut Henri Poin-
caré 7. 1937:pages 1–68.
24. West D. Ternary Equilibrium Diagrams 2nd. edition: Springer; 2013.
25. Cannings C, Edwards AW. Natural selection and the de Finetti diagram. Annals of human genetics.
1968; 31(4):421–8. PMID: 5673165.
26. Kohonen T. Self-organized formation of topologically correct feature maps. Biological Cybernetics.
1982; 43(1):59–69. doi: 10.1007/BF00337288
27. Cao Q, Zhou M, Wang X, Meyer CA, Zhang Y, Chen Z, et al. CaSNP: a database for interrogating copy
number alterations of cancer genome from SNP array data. Nucleic acids research. 2011; 39(Database
issue):D968–74. doi: 10.1093/nar/gkq997 PMID: 20972221; PubMed Central PMCID: PMC3013814.
28. Zilliox MJ, Irizarry RA. A gene expression bar code for microarray data. Nature methods. 2007; 4
(11):911–3. doi: 10.1038/nmeth1102 PMID: 17906632; PubMed Central PMCID: PMC3154617.
29. McCall MN, Jaffee HA, Zelisko SJ, Sinha N, Hooiveld G, Irizarry RA, et al. The Gene Expression Bar-
code 3.0: improved data processing and mining tools. Nucleic acids research. 2014; 42(Database
issue):D938–43. doi: 10.1093/nar/gkt1204 PMID: 24271388; PubMed Central PMCID: PMC3965035.
30. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation
response. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98
(9):5116–21. doi: 10.1073/pnas.091062498 PMID: 11309499; PubMed Central PMCID: PMC33173.
31. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids
of gene expression. Proceedings of the National Academy of Sciences of the United States of America.
2002; 99(10):6567–72. doi: 10.1073/pnas.082099299 PMID: 12011421; PubMed Central PMCID:
PMC124443.
32. Hartigan JA. Clustering algorithms. 99 ed: JohnWiley & Sons; 1975.
Common Genomic Fingerprints of Human Cancers
PLOS ONE | DOI:10.1371/journal.pone.0161514 August 18, 2016 14 / 14
